Allogene Therapeutics (ALLO) Research & Development (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Research & Development data on file, last reported at $32.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 36.25% year-over-year to $32.0 million; the trailing twelve-month figure through Mar 2026 stood at $132.0 million (down 30.64% YoY), and the FY2025 full-year result was $150.2 million, down 21.92% from the prior year.
• Research & Development advanced to $32.0 million in Q1 2026, from $28.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $80.2 million in Q1 2023 to a low of $28.6 million in Q4 2025.
• A 5-year average of $51.4 million and a median of $50.4 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 39.71% in 2022 and plunged 36.33% in 2025, its largest moves.
• Tracing ALLO's Research & Development over 5 years: stood at $75.4 million in 2022, then retreated by 27.52% to $54.7 million in 2023, then decreased by 17.73% to $45.0 million in 2024, then sank by 36.33% to $28.6 million in 2025, then rose by 11.77% to $32.0 million in 2026.
• Business Quant data shows ALLO's Research & Development at $32.0 million in Q1 2026, $28.6 million in Q4 2025, and $31.2 million in Q3 2025.